NPC(SH:600713)2014-04-29 16:00Financial Performance - Operating revenue for the first quarter reached CNY 5,252,365,460.96, representing a 12.71% increase year-on-year[10] - Net profit attributable to shareholders increased by 120.43% to CNY 10,337,166.34 compared to the same period last year[10] - Operating profit reached RMB 18,951,331.77, reflecting a significant increase of 129.75% from RMB 8,248,632.68 year-on-year[17] - Total operating revenue for the current period reached ¥5,252,365,460.96, an increase of 12.68% compared to ¥4,660,091,083.64 in the previous period[36] - Net profit attributable to the parent company was ¥10,337,166.34, compared to ¥4,689,615.86 in the previous period, representing a growth of 120.00%[37] - Basic earnings per share improved to ¥0.015 from ¥0.007, indicating a 114.29% increase[37] Cash Flow - Cash flow from operating activities showed a negative value of CNY -154,093,241.23, an improvement from CNY -210,495,925.67 in the previous year[10] - Total cash inflow from operating activities was RMB 4,744,477,757.20, up 67.17% from RMB 2,838,150,703.85 year-on-year[18] - Cash received from sales of goods and services amounted to RMB 4,664,097,915.25, representing a 75.90% increase from RMB 2,651,490,366.61 in the previous year[18] - Cash flow from financing activities generated a net inflow of RMB 126,180,202.00, compared to a net outflow of RMB 94,377,181.49 in the same period last year[19] - Cash flow from operating activities generated a net outflow of ¥154,093,241.23, an improvement from a net outflow of ¥210,495,925.67 in the previous period[42] - Financing activities generated a net cash inflow of ¥126,180,202.00, contrasting with a net outflow of ¥94,377,181.49 previously[43] Assets and Liabilities - Total assets increased by 6.15% to CNY 10,476,843,085.46 compared to the end of the previous year[10] - The company's total current assets reached CNY 9,085,892,921.23, up from CNY 8,454,576,438.03, indicating an increase of about 7.44%[28] - The total liabilities increased to CNY 9,194,476,940.61 from CNY 8,531,049,310.76, reflecting a rise of approximately 7.77%[30] - The company's total equity decreased to CNY 1,282,366,144.85 from CNY 1,338,583,487.83, a decline of approximately 4.20%[30] - The total current liabilities increased to CNY 8,956,609,751.42 from CNY 8,292,881,504.72, reflecting a growth of about 7.99%[30] Investments - Long-term equity investments decreased by 30.34% to CNY 137,427,913.72 due to equity swaps[16] - The company's long-term investments decreased to CNY 137,427,913.72 from CNY 197,269,900.09, a decline of approximately 30.38%[29] - The company reported a total of CNY 7,280,411.72 in non-operating income for the quarter[11] Shareholder Information - The number of shareholders reached 59,880 by the end of the reporting period[12] - The largest shareholder, Nanjing Pharmaceutical Group, holds 21.00% of the shares, totaling 145,657,368 shares[12] Operational Changes - The company completed a share swap with Nanjing Jinling Pharmaceutical Group, integrating Fujian Southeast Pharmaceutical Co., Ltd. into its consolidated financial statements[20] - The company received approval from the Ministry of Commerce for strategic investment from Alliance Healthcare Asia Pacific Limited[21] - The company is actively working to resolve competition issues related to its subsidiaries, with several changes in ownership completed[24]